PepGen(US:PEPG) Prnewswireยท2025-07-11 13:00Core Viewpoint - A class action securities lawsuit has been filed against PepGen Inc. due to alleged securities fraud affecting investors between March 7, 2024, and March 3, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that PepGen's lead product candidate, PGN-EDO51, was misrepresented as being more effective and safe than it actually is [2]. - It is alleged that the phase two CONNECT2 study was dangerous or deficient for FDA approval, leading to the likelihood of halting the study [2]. - The complaint asserts that the public statements made by the defendants were materially false and misleading throughout the relevant period [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until August 8, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions of dollars for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].